2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ
BACILLUS CALMETTE-GUÉRIN (BCG) plus N-803 (also known as ALT-803) demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS), according to results from cohort A of the phase 2/3 QUILT-3.032 study (NCT03022825).1
The findings, presented during the 2021 Genitourinary Cancers Symposium, showed that at a median follow-up of 10.7 months, 71% of evaluable patients (51/72) achieved a complete response (CR) at any time (95% CI, 59%-81%), meeting the primary end point of the study.
Moreover, investigators reported a 56% probability of maintaining a CR with this approach at 12 months (95% CI, 38.8%-70.3%). Among responders, the estimated median duration of CR was 19.2 months (95% CI, 7.3–not reached). Notably, the majority of patients, or 87.5% (70/80), have not progressed to radical cystectomy.
“N-803 is an interleukin [IL]-15 superagonist antibody cytokine fusion protein with significant binding capacity to the IL-2R beta and gamma and increased half-life of the Fc receptor,” Karim Chamie, MD, MSHS, lead study author and an associate professor in residence of urology and the Society of Urologic Oncology fellowship director at the University of California, Los Angeles, explained during a presentation on the findings. “This results in significant accrual of T cells and natural killer cells without upregulation of regulatory T cells.”
Results from the phase 1 trial examining N-803 plus BCG indicated that all patients (n = 9) with high-risk NMIBC experienced a durable CR or no recurrence. All patients were disease free at 24 months. Based on these data, the FDA granted N-803 a fast track therapy designation in December 2019; this led to the launch of the phase 2/3 trial to further examine this approach.2
To be eligible for enrollment on the trial, patients had to have histologically confirmed BCG-unresponsive CIS with or without Ta or T1 disease. Investigators defined BCG-unresponsive disease as persistent or recurrent CIS within 12 months of being treated with BCG; further, at least 5 of 6 doses of initial induction course with at least 2 of 3 doses of maintenance treatment or at least 2 of 6 doses of a second induction course were required to meet the definition.
Eighty patients were enrolled to cohort A, and they received 50 mg of BCG in combination with 400 μg of N-803 intravesically weekly x6 induction or single reinduction x3 plus maintenance.
The primary end point of the study is CR at any time with a lower-bound 95% confidence interval of 20% or greater. At least 24 of the 80 patients enrolled needed to have experienced a CR to meet this end point. Key secondary end points included duration of CR and CR rate at 6 and 12 months. Other end points included progression-free survival, time to cystectomy, cystectomy rate, overall survival, and CR rate at any time per central pathology review.
The mean age of patients enrolled on the study was 72.5 years, with 84% of patients 65 years or older. The majority of patients were male (86%) and White (90%). Eighty-two percent of patients had an ECOG performance status of 0, whereas 18% had a status of 1.
The mean and median times from last previous BCG dose to study entry were 8.0 months and 6.2 months, respectively. Additionally, the mean and median times from last prior BCG dose to first detected recurrence were 3.6 months and 2.7 months, respectively. Moreover, the mean and median times from first detected recurrence to study entry were 4.6 and 2.3 months, respectively. The majority of patients had CIS at first recurrence (69%); 21% had CIS/Ta and 9% had CIS/T1.
“This is a heavily pretreated cohort. The median number of transurethral resections of the bladder tumor was 5.0, and the median number of prior BCG instillations was 16.2,” said Chamie. “One hundred percent of patients received prior BCG. In addition to that, 78% of patients received additional therapy with BCG, including checkpoint inhibitors [3%], chemotherapy [59%], interferon [13%], and vicinium [3%].”
N-803 showed promising results vs other FDA-approved agents or investigational therapeutics in the space. Pembrolizumab (Keytruda), for example, yielded a 41% CR rate at any time and a median duration of response of 16.2 months in responders.3 Similarly, nadofaragene firadenovec (rAd-IFNa/ Syn3) elicited a 53% CR rate at any time with a median duration of response of 9.7 months.4
“N-803 had a smaller cohort. However, the CR rate at any time was much higher, at 71% vs 41% and 53% for pembrolizumab and nadofaragene [firadenovec], respectively,” Chamie reported. “Our median duration was also favorable, although this must be taken within the context of a shorter median follow-up of 10.7 months. The cystectomy-free rate of 88% also compares favorably, with only 1 of 10 patients demonstrating extravesical disease.”
The most common any-grade treatment-related adverse effects (TRAEs) included dysuria (18%), hematuria (15%), and pollakiuria (14%). Grade 3 or higher TRAEs were rare but observed during the study, with grade 3 arthralgia, myalgia, and extremity pain each reported in 1% of patients. Serious AEs were also rare but included cardiac disease (1%), hematuria (1%), and adenocarcinoma of the colon (1%).
No serious TRAEs, no immune-related systemic AEs, and no grade 5 TRAEs were reported. Moreover, no TRAEs led to treatment discontinuation.
“This administration profile is familiar to urologists and favorable as an intravesical agent,” concluded Chamie.